Evaluation of Cognitive Improvement After Bariatric Surgery Using a Virtual Reality Program and the Neuropsi Neuropsychological Battery
Recruiting now NCT07229924
Run by Hospital General de México Dr. Eduardo Liceaga · for 18 to 65 · All sexes · accepts healthy volunteers
What this study is about
Background: Obesity is a chronic, systemic, and multifactorial disease affecting populations worldwide, with projections indicating a 50% increase by 2035. It is linked to higher risks of cognitive decline, brain atrophy, and neurodegenerative diseases like Alzheimer's. Bariatric surgery has shown benefits in reducing fat and systemic inflammation, which may improve cognitive function. However, the factors predicting such improvements remain unclear. Objective: To evaluate the effect of bariatric surgery on cognitive performance using virtual reality (Neurotracker) and the Neuropsi neuropsychological battery. Methods: This prospective quasi-experimental study will include patients with morbid obesity who are candidates for bariatric surgery. Cognitive performance will be evaluated using the Neurotracker virtual reality tool and the Neuropsi neuropsychological battery. Participants will complete Neurotracker sessions three times weekly for two weeks before surgery, and again at 3- and 6-months post-surgery. The Neuropsi assessment will be conducted once prior to surgery and repeated at 6 months afterward. Statistical analyses will compare cognitive performance before and after the surgical intervention. Expected Outcomes: The study aims to identify measurable improvements in cognitive function after weight loss from bariatric surgery, evaluated through both traditional neuropsychological tests and immersive virtual reality tools. These results could improve understanding of the cognitive benefits of surgical obesity treatment and the factors that predict these outcomes.
Who can join (things the study team will check)
Inclusion Criteria: A. Age (18-65 years) B. Diagnostic of morbid obesity with a body mass index (BMI) \> 40 kg/m2, or, C. Obesity grade II (BMI \> 35 kg/m2) and associated comorbidities (Diabetes Mellitus type 2, Hypertension, Ischemic Cardiopathy, Hyperlipidemia, Hepatic Steatosis, Metabolic Syndrome, Obstructive Sleep Apnea, Pickwick Syndrome) D. Bariatric surgery criteria. Exclusion Criteria: A. Age \< 18 years, \> 65 years B. Visual impairment C. Personal history of CVE D. Drug addiction.…
Where this trial is running
- Faubert Lab, Montreal, Quebec, Canada
- Hospital General de México "Dr. Eduardo Licega", Mexico City, Mexico City, Mexico
Who to contact
Argelia Pérez Pacheco, PhD · +525527892000 · argeliapp@ciencias.unam.mx
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07229924.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.